• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Sanofi, Janssen to Collaborate on Extraintestinal Pathogenic E. Coli Vaccine


Currently in Phase III of clinical trials, Sanofi is expected to commercialize vaccine candidate.

E.Coli Bacteria Cells 3D Illustration. Image Credit: Adobe Stock Images/Ezume Images

Image Credit: Adobe Stock Images/Ezume Images

Sanofi announced in a company press release that it has agreed to terms with Janssen, a Johnson & Johnson company, to develop and commercialize a vaccine candidate for extraintestinal pathogenic E. coli (9-valent), currently in Phase III of clinical trials at Janssen. As per the deal, the two organizations will co-fund current and future research and development costs. Sanofi will provide an upfront payment of $175M Janssen, followed by development and commercial milestones.

“E. coli is a significant cause of sepsis, mortality, and antimicrobial resistance in older adults, and the number of cases is rising as the population ages,” said Thomas Triomphe, EVP, vaccines, Sanofi. “In line with our commitment to design and deliver first- or best-in-class medicines and vaccines, this agreement with Janssen aims to positively impact public health by reducing hospitalization costs and the burden on health systems associated with ExPEC and help older adults around the world to live longer, healthier lives.”

Reference: Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli. Sanofi. October 3, 2023. Accessed October 3, 2023. https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-03-05-30-00-2753274

Related Videos
Related Content